Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors.
Yuman Fong, MD on Safety of Gene-Edited Autologous NeoTCR-P1 #AACR2020
